Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sangamo Therapeutics (SGMO) Other Working Capital Changes (2016 - 2025)

Sangamo Therapeutics has reported Other Working Capital Changes over the past 16 years, most recently at -$9.9 million for Q4 2025.

  • Quarterly results put Other Working Capital Changes at -$9.9 million for Q4 2025, down 358.29% from a year ago — trailing twelve months through Dec 2025 was -$6.7 million (down 2510.59% YoY), and the annual figure for FY2025 was -$6.7 million, down 2510.59%.
  • Other Working Capital Changes for Q4 2025 was -$9.9 million at Sangamo Therapeutics, down from $3.2 million in the prior quarter.
  • Over the last five years, Other Working Capital Changes for SGMO hit a ceiling of $154.4 million in Q3 2023 and a floor of -$149.8 million in Q1 2023.
  • Median Other Working Capital Changes over the past 5 years was $18000.0 (2024), compared with a mean of -$239150.0.
  • Biggest five-year swings in Other Working Capital Changes: soared 9073.31% in 2022 and later crashed 62243.57% in 2023.
  • Sangamo Therapeutics' Other Working Capital Changes stood at $708000.0 in 2021, then soared by 9073.31% to $64.9 million in 2022, then crashed by 107.93% to -$5.1 million in 2023, then soared by 174.31% to $3.8 million in 2024, then crashed by 358.29% to -$9.9 million in 2025.
  • The last three reported values for Other Working Capital Changes were -$9.9 million (Q4 2025), $3.2 million (Q3 2025), and $1.3 million (Q2 2025) per Business Quant data.